Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01744652 · ClinicalTrials.gov registry record · Phase 1
Dasatinib and Crizotinib in Advanced Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT01744652: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01744652 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 62 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01744652, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib and crizotinib that can be given to patients with advanced cancer. The safety of this drug combination will also be studied. Dasatinib is designed to block certain proteins from causing cancer cells to grow out of control. This may cause the cancer cells to die. Crizotinib is designed to block certain abnormal genes found in cancer cells. This may cause the cancer cells to die. This is an investigational study. Dasatinib is FDA approved and commercially available for the treatment of leukemia. Crizotinib is FDA approved and commercially available for the treatment of lung cancer. The combination of dasatinib and crizotinib is currently being used for research purposes only. Up to 176 participants will take part in this study. All will be enrolled at MD Anderson
Interventions
- DRUG Dasatinib
- DRUG Crizotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2013-03 |
| Est. Completion | 2019-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01744652
The ClinicalTrials.gov registry entry for NCT01744652 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib is the first listed.
NCT01744652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01744652 about?
NCT01744652 is a clinical study titled "Dasatinib and Crizotinib in Advanced Cancer". The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib and crizotinib that can be given to patients with advanced cancer. The safety of this drug combination will also be studied. Dasatinib is designed to block certain proteins from causing ca...
What is the current status of trial NCT01744652?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2013-03. Estimated completion is 2019-03.
What interventions are being tested in trial NCT01744652?
The interventions under investigation include: Dasatinib (DRUG), Crizotinib (DRUG).
Who is sponsoring clinical trial NCT01744652?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.